Therapies for bleomycin induced lung fibrosis through regulation of TGF-β1 induced collagen gene expression

168Citations
Citations of this article
80Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

This review describes normal and abnormal wound healing, the latter characterized by excessive fibrosis and scarring, which for lung can result in morbidity and sometimes mortality. The cells, the extracellular matrix (ECM) proteins, and the growth factors regulating the synthesis, degradation, and deposition of the ECM proteins will be discussed. Therapeutics with particular emphasis given to gene therapies and their effects on specific signaling pathways are described. Bleomycin (BM), a potent antineoplastic antibiotic increases TGF-β1 transcription, TGF-β1 gene expression, and TGF-β protein. Like TGF-β1, BM acts through the same distal promoter cis-element of the COL1A1 gene causing increased COL1 synthesis and lung fibrosis. Lung fibroblasts exist as subpopulations with one subset predominately responding to fibrogenic stimuli which could be a specific cell therapeutic target for the onset and development of pulmonary fibrosis. © 2007 Wiley-Liss, Inc.

Cite

CITATION STYLE

APA

Cutroneo, K. R., White, S. L., Phan, S. H., & Ehrlich, H. P. (2007, June). Therapies for bleomycin induced lung fibrosis through regulation of TGF-β1 induced collagen gene expression. Journal of Cellular Physiology. https://doi.org/10.1002/jcp.20972

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free